Loading...
Market
What will be the primary focus of the Gabriella Miller Kids First Research Act 2.0 funding allocation by December 31, 2025?
2
Resolution / Starting Odds
Genetic research • 25%
Clinical trials • 25%
Data infrastructure • 25%
Other • 25%
Official announcements from the National Institutes of Health or related agencies
Story
Senate Passes $190 Million Pediatric Cancer Research Bill, H.R.3391, After House Approval on March 5, 2024, by 384-4 Vote
Dec 20, 2024, 08:40 PM
A $190 million funding bill for pediatric cancer research, known as the Gabriella Miller Kids First Research Act 2.0, was passed by the Republican-controlled House on March 5, 2024, with an overwhelming vote of 384-4. However, the bill has been stalled in the Democrat-controlled Senate, where Senate Majority Leader Chuck Schumer has not brought it up for a vote. This situation has led to accusations against Democrats for allegedly using the funding as a bargaining chip in broader negotiations. Recently, the Senate passed the bill unanimously, allowing it to move to President Biden for final approval. The bill's passage comes after a period of intense political discourse, where Democrats were criticized for blaming Republicans for the funding's delay, despite the bill's prior approval in the House.
View original story
Similar markets
Majority to existing programs • 25%
Majority to new initiatives • 25%
Even split between existing and new • 25%
Other allocation strategy • 25%
Tumor-removal technologies • 25%
Cancer screening and early detection • 25%
Cancer treatment in underserved communities • 25%
Other • 25%
Technology development for surgeons • 25%
Cancer screenings • 25%
Follow-up treatments • 25%
Other • 25%
Significant advancements • 25%
Moderate advancements • 25%
Minimal advancements • 25%
No noticeable advancements • 25%
Pandemic Preparedness • 25%
Chronic Disease Research • 25%
Mental Health Initiatives • 25%
Other • 25%
COVID-19 management • 25%
Cancer research • 25%
Mental health • 25%
Other • 25%
Passed • 25%
Rejected • 25%
Amended • 25%
No Action • 25%
Increased funding for infectious disease research • 25%
Increased funding for chronic disease research • 25%
Increased funding for mental health research • 25%
Other funding priorities • 25%
Increase Funding • 25%
Decrease Funding • 25%
Change Allocation • 25%
No Amendments • 25%
Increased focus on chronic diseases • 25%
Maintained current balance • 25%
Increased focus on infectious diseases • 25%
No significant changes • 25%
Autism • 25%
Cognitive Development • 25%
Neoteny • 25%
Other • 25%